JP2019146574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019146574A5 JP2019146574A5 JP2019071336A JP2019071336A JP2019146574A5 JP 2019146574 A5 JP2019146574 A5 JP 2019146574A5 JP 2019071336 A JP2019071336 A JP 2019071336A JP 2019071336 A JP2019071336 A JP 2019071336A JP 2019146574 A5 JP2019146574 A5 JP 2019146574A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- hiv
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200138 | 2015-12-15 | ||
| EP15200138.4 | 2015-12-15 | ||
| EP16194124 | 2016-10-17 | ||
| EP16194124.0 | 2016-10-17 | ||
| JP2018531537A JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Division JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019146574A JP2019146574A (ja) | 2019-09-05 |
| JP2019146574A5 true JP2019146574A5 (enExample) | 2020-02-06 |
| JP6959289B2 JP6959289B2 (ja) | 2021-11-02 |
Family
ID=57737697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Active JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
| JP2019071336A Expired - Fee Related JP6959289B2 (ja) | 2015-12-15 | 2019-04-03 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Active JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10369214B2 (enExample) |
| EP (3) | EP3390430B1 (enExample) |
| JP (2) | JP6510149B2 (enExample) |
| KR (1) | KR102960814B1 (enExample) |
| CN (2) | CN108368157B (enExample) |
| AU (2) | AU2016369326B2 (enExample) |
| BR (1) | BR112018011122A2 (enExample) |
| CA (1) | CA3008542C (enExample) |
| CY (2) | CY1122705T1 (enExample) |
| DK (2) | DK3584252T3 (enExample) |
| EA (1) | EA038974B1 (enExample) |
| ES (2) | ES2753854T3 (enExample) |
| HR (2) | HRP20211566T1 (enExample) |
| HU (2) | HUE045993T2 (enExample) |
| IL (1) | IL259942B2 (enExample) |
| LT (2) | LT3584252T (enExample) |
| MA (3) | MA55825A (enExample) |
| MD (2) | MD3584252T2 (enExample) |
| ME (1) | ME03545B (enExample) |
| MX (2) | MX383507B (enExample) |
| PH (1) | PH12018501047A1 (enExample) |
| PL (2) | PL3390430T3 (enExample) |
| PT (1) | PT3390430T (enExample) |
| RS (2) | RS59447B1 (enExample) |
| SG (2) | SG10202109457RA (enExample) |
| SI (2) | SI3584252T1 (enExample) |
| SM (2) | SMT201900629T1 (enExample) |
| TW (2) | TWI792091B (enExample) |
| WO (1) | WO2017102929A1 (enExample) |
| ZA (1) | ZA201803978B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40765B1 (fr) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| PL3390430T3 (pl) | 2015-12-15 | 2020-03-31 | Janssen Vaccines & Prevention B.V. | Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania |
| EA201892735A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Вэксинс Энд Превеншн Б.В. | Состав вакцины против hiv |
| CA3035759A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| JP7178344B2 (ja) | 2016-09-15 | 2022-11-25 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化ｈｉｖエンベロープタンパク質変異 |
| BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| MY200554A (en) * | 2017-07-19 | 2024-01-03 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| AU2018366480C1 (en) * | 2017-11-17 | 2024-02-01 | Grifols Diagnostic Solutions Inc. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
| CN114269363A (zh) * | 2019-04-17 | 2022-04-01 | 威斯达研究所 | 用于hiv疫苗应用的复制缺陷型腺病毒载体 |
| TW202110476A (zh) | 2019-05-22 | 2021-03-16 | 荷蘭商傑森疫苗防護公司 | 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法 |
| CA3159907A1 (en) | 2019-11-07 | 2021-05-14 | Janssen Vaccines & Prevention B.V. | Protein purification |
| CA3182703A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| WO2021249011A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022006095A2 (en) * | 2020-06-29 | 2022-01-06 | Duke University | Mosaic hiv-1 envelopes to induce adcc responses |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| KR20230150269A (ko) | 2021-02-23 | 2023-10-30 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 외피 단백질 돌연변이를 안정화시키는 삼량체 |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
| ATE519854T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus auf basis von serotyp 48 (ad48). |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| WO2001019958A2 (en) | 1999-09-17 | 2001-03-22 | Dana-Farber Cancer Institute, Inc. | Stabilized soluble glycoprotein trimers |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| CA2785699A1 (en) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP1409694A4 (en) * | 2001-07-05 | 2006-02-08 | Chiron Corp | POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF |
| EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| US7901690B2 (en) | 2002-12-03 | 2011-03-08 | University Of Massachusetts | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
| WO2004087201A2 (en) | 2003-03-28 | 2004-10-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mva virus expressing modified hiv envelope, gag, and pol genes |
| WO2005027840A2 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
| WO2005035555A1 (en) | 2003-10-10 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies |
| WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
| JP4814800B2 (ja) | 2004-01-23 | 2011-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | チンパンジーアデノウイルスワクチン担体 |
| WO2005110492A2 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
| WO2006002079A2 (en) | 2004-06-15 | 2006-01-05 | Progenics Pharmaceuticals, Inc. | Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex |
| EP2397490B1 (en) * | 2004-07-16 | 2013-09-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV |
| WO2006026667A2 (en) * | 2004-08-27 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
| US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP2040747A4 (en) | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE |
| EP2073840A4 (en) | 2006-10-23 | 2010-10-27 | Progenics Pharm Inc | MODIFIED GP140-HOLL-POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERS, COMPLEXES, AND ITS USES |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| CN103550764A (zh) | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| PL2358757T3 (pl) | 2008-11-18 | 2019-02-28 | Beth Israel Deaconess Medical Center | Szczepionki antywirusowe o ulepszonej immunogenności komórkowej |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| HUE039908T2 (hu) | 2009-02-02 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| WO2011082087A2 (en) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Dps fusion proteins for use in vaccines and diagnostics |
| NZ600629A (en) | 2010-01-28 | 2014-12-24 | Bavarian Nordic As | Vaccinia virus mutants containing the major genomic deletions of mva |
| CA3201524C (en) | 2010-08-31 | 2026-01-13 | International Aids Vaccine Initiative | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| KR101879892B1 (ko) | 2010-12-14 | 2018-08-17 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 |
| JP6407714B2 (ja) * | 2011-04-25 | 2018-10-17 | アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド | 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物 |
| US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| WO2013040766A1 (zh) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 可诱导针对hiv的广谱免疫应答的方法和疫苗 |
| WO2013055908A1 (en) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | An hiv-1 gp120 mini v3 loop and uses thereof |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| CA2891349C (en) | 2012-11-16 | 2023-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| WO2014107744A1 (en) | 2013-01-07 | 2014-07-10 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| US10248758B2 (en) | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| EP3666790A1 (en) * | 2013-10-04 | 2020-06-17 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
| JP2017507672A (ja) * | 2014-02-28 | 2017-03-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法 |
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| MA40765B1 (fr) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| EP3271729B1 (en) * | 2015-03-18 | 2020-09-23 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
| PL3390430T3 (pl) | 2015-12-15 | 2020-03-31 | Janssen Vaccines & Prevention B.V. | Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania |
| EA201892735A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Вэксинс Энд Превеншн Б.В. | Состав вакцины против hiv |
| CA3035759A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| JP7178344B2 (ja) | 2016-09-15 | 2022-11-25 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化ｈｉｖエンベロープタンパク質変異 |
| DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active IP Right Grant
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/me unknown
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 MX MX2018007198A patent/MX383507B/es unknown
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 SM SM20190629T patent/SMT201900629T1/it unknown
- 2016-12-15 KR KR1020187016460A patent/KR102960814B1/ko active Active
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 CA CA3008542A patent/CA3008542C/en active Active
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/en not_active Ceased
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/en active Active
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh not_active IP Right Cessation
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro not_active IP Right Cessation
- 2016-12-15 SM SM20210623T patent/SMT202100623T1/it unknown
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro not_active IP Right Cessation
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh not_active IP Right Cessation
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/en not_active Withdrawn
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/en active Active
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja not_active Expired - Fee Related
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211566T1 (hr) | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe | |
| Kinney et al. | Nucleotide sequence of the 26 S mRNA of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and deduced sequence of the encoded structural proteins | |
| US8389275B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| JP6306514B2 (ja) | Ｈｉｖワクチン接種のための免疫原 | |
| CN110958887B (zh) | 编码hiv抗原的痘病毒载体及其使用方法 | |
| KR20120083899A (ko) | 마이코박테리아 백신들 | |
| JP2019527055A5 (enExample) | ||
| RU2015155821A (ru) | Вакцины против малярии | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| JP2017531693A5 (enExample) | ||
| JP2019214579A5 (enExample) | ||
| US20090227658A1 (en) | Methods and compositions for immunization against hiv | |
| KR20200100745A (ko) | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 | |
| AU2020279988A1 (en) | Dosage regimens for vaccines | |
| JP6612237B2 (ja) | ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター | |
| Hara et al. | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors | |
| Bongard et al. | Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| Chen et al. | Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses | |
| WO2023092023A2 (en) | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) | |
| Podschwadt et al. | A detailed analysis of F-MuLV-and SFFV-infected cells in Friend virus-infected mice reveals the contribution of both F-MuLV-and SFFV-infected cells to the interleukin-10 host response | |
| Huisman et al. | Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats |